8.8 C
London
Thursday, March 28, 2024
HomeFinTechRecce Pharmaceuticals: Receives positive safety data from second cohort of Phase I...

Recce Pharmaceuticals: Receives positive safety data from second cohort of Phase I Clinical Trial

Date:

Recce Pharmaceuticals Receives positive safety data from second cohort of Phase I Clinical Trial

  • Recce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects for its Phase I intravenous clinical trial of RECCE 327 (R327)
  • R327 is designed to treat serious bacterial infections including sepsis.
  • The second cohort demonstrated safety and tolerability among seven healthy male subjects who were intravenously dosed with 150mg of R327
  • An independent safety committee has approved an increase in dosage to 500mg in the third cohort
  • Shares were trading 2.69 per cent higher today at $1.34 at the end of the trading day

Related stories

UK paytech Volopa partners ClearBank to expand its SME banking services

London-based paytech Volopa has partnered with embedded banking...

Digital identity specialist Signicat acquires Icelandic counterpart SmartWorks

Signicat, a European provider of digital identity solutions,...

BNY Mellon deploys AI supercomputer from Nvidia

BNY Mellon, a US-based banking heavyweight, has deployed...

Colombian BNPL firm Addi lands $86m in equity and debt funding

Colombian buy now, pay later (BNPL) firm Addi...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img